GLP-1
The natural appetite hormone that your gut produces after eating — it's what all GLP-1 weight loss drugs (semaglutide, tirzepatide, etc.) are designed to copy. Your body makes it naturally, but it breaks down within 1-2 minutes, which is far too fast to use as a medicine. That's why drug companies created modified versions that last days instead of minutes. Included here because understanding GLP-1 is key to understanding the entire class of modern weight loss drugs.
Dosage
Not used therapeutically — all approved therapies use modified analogues
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Blood Sugar Control
Glucose-dependent insulin secretion and glucagon suppression.
Appetite Suppression
Hypothalamic signaling reduces hunger — the basis for all GLP-1 drugs.
Gastric Emptying
Slows stomach emptying, helping you feel full longer after meals.
Mechanism of Action
GLP-1 (glucagon-like peptide 1) is the native incretin hormone produced by enteroendocrine L-cells in the distal small intestine and colon in response to nutrient ingestion. It is the endogenous molecule that all GLP-1 receptor agonist drugs (semaglutide, liraglutide, etc.) are designed to mimic. Understanding native GLP-1 is essential to understanding the entire drug class built upon its biology.
Upon release, GLP-1 binds to GLP-1 receptors (GLP-1R) — G protein-coupled receptors expressed on pancreatic beta cells, the GI tract, the heart, the kidneys, and critically, the brain. In the pancreas, GLP-1R activation stimulates adenylyl cyclase, raising intracellular cAMP levels, which potentiates glucose-stimulated insulin secretion. This glucose-dependence is a key safety feature — GLP-1 only promotes insulin release when blood sugar is elevated, minimizing hypoglycemia risk. Simultaneously, GLP-1 suppresses glucagon secretion from alpha cells, further reducing hepatic glucose output.
In the brain, GLP-1 receptors in the hypothalamus (arcuate nucleus, paraventricular nucleus) and brainstem (area postrema, nucleus tractus solitarius) mediate appetite suppression and satiety. GLP-1 also activates vagal afferents to slow gastric emptying, prolonging nutrient absorption and post-meal satiety. The critical limitation of native GLP-1 is its extremely rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves the first two amino acids within 1-2 minutes, rendering it inactive. This ultra-short half-life is why pharmaceutical GLP-1 analogues require structural modifications (albumin binding, DPP-4 resistance) to achieve clinically useful durations of action.
Regulatory Status
Not available as an approved drug in native form. All approved GLP-1 therapies are modified analogues with extended half-lives.
Risks & Safety
Common
nausea and vomiting at higher doses.
Serious
dangerously low blood sugar if combined with insulin or diabetes medications.
Rare
allergic reactions.
Compare GLP-1 With
Research Papers
32Published: February 11, 2026
AI Summary
GLP-1 drugs show promise in lab models of ALS but current clinical data do not support their use and raise safety concerns, especially around weight loss. More ALS-specific trials are needed before considering these drugs for this population.
Published: February 11, 2026
AI Summary
Weight-loss drugs that mimic GLP-1 mainly reduce appetite but do little to boost energy expenditure. Glucagon receptor agonists may help by increasing fat burning and metabolic rate, potentially improving long-term weight loss when combined with GLP-1 drugs.
Published: February 11, 2026
AI Summary
GLP-1 drugs like semaglutide are widely used for diabetes and weight loss, but emerging reports suggest a possible link to a rare form of vision loss. The abstract highlights the need to weigh this potential risk.
Published: February 11, 2026
AI Summary
The Sim-Q questionnaire was developed to measure how simple or complex diabetes treatment feels to patients. The study evaluated whether the questionnaire is reliable and valid for use in type 2 diabetes.
Published: February 11, 2026
AI Summary
Obesity caused by hypothalamic damage is hard to treat with diet and exercise alone, but newer drugs targeting appetite and metabolism show promise. Combination therapies may eventually reduce the need for bariatric surgery in this population.
Published: February 11, 2026
AI Summary
Kuwaiti experts recommend earlier screening, better coordination across specialties, and broader use of GLP-1 drugs to address the overlapping burdens of obesity, diabetes, heart disease, and kidney disease. Semaglutide was highlighted as a valuable option.
Published: February 11, 2026
AI Summary
GLP-1 drugs were linked to modest weight loss and better overall survival in breast cancer survivors in a real-world study. The drugs did not affect disease-free survival, but clinical trials are warranted in this population.
Published: February 11, 2026
AI Summary
Abstract too short to summarize.
Published: February 4, 2026
AI Summary
Limited fMRI data suggest GLP-1 drugs may reduce brain reactivity to food cues, but results are inconsistent and may fade over time. Larger, standardized studies are needed, including for drug and alcohol cues.
Published: January 26, 2025
AI Summary
Abstract too short to summarize.
Published: February 11, 2026
AI Summary
Abstract too short to summarize.
Published: February 10, 2026
AI Summary
Long-term GLP-1 use before spine surgery was linked to fewer postoperative complications in overweight adults. The drugs may improve surgical outcomes in this population.
Published: January 21, 2026
AI Summary
Abstract too short to summarize.
Published: February 8, 2026
AI Summary
The oral semaglutide enhancer SNAC altered gut bacteria, reduced butyrate, and raised inflammatory markers in rats. The findings suggest a need for delivery methods that are gentler on the microbiome.
Published: February 8, 2026
AI Summary
GLP-1 affects metabolism, inflammation, and aging through multiple pathways and may have uses beyond diabetes. The review calls for better formulations, biomarkers, and studies in age-related disease.
Published: February 9, 2026
AI Summary
Abstract too short to summarize.
Published: February 9, 2026
AI Summary
Abstract too short to summarize.
Published: February 10, 2026
AI Summary
Abstract too short to summarize.
Published: February 10, 2026
AI Summary
Abstract too short to summarize.
Published: February 10, 2026
AI Summary
Abstract too short to summarize.
Published: January 9, 2026
AI Summary
Semaglutide improved acne, hidradenitis suppurativa, and sebum production over 24 months, with changes tied to metabolic improvements. The findings support further study of GLP-1 drugs for skin conditions.
Published: February 18, 2026
AI Summary
Abstract too short to summarize.
Published: February 10, 2026
AI Summary
Abstract too short to summarize.
Published: February 8, 2026
AI Summary
Abstract too short to summarize.
Published: February 8, 2026
AI Summary
Semaglutide protected cartilage in obese mice with osteoarthritis through a metabolic pathway independent of weight loss. The drug shifted chondrocyte metabolism from glycolysis to oxidative phosphorylation.
Published: February 1, 2026
AI Summary
A case report linked semaglutide to pleural and pericardial effusions in a 70-year-old patient. As use grows, new adverse events may emerge that warrant monitoring.
Published: February 9, 2026
AI Summary
Abstract too short to summarize.
Published: February 1, 2026
AI Summary
Abstract too short to summarize.
Published: February 9, 2026
AI Summary
Abstract too short to summarize.
Published: February 9, 2026
AI Summary
Abstract too short to summarize.
Published: February 9, 2026
AI Summary
A systematic review evaluated how diabetes drugs, including GLP-1 agonists, affect fatty liver disease. The findings may guide treatment choices for patients with both diabetes and liver disease.
Published: February 9, 2026
AI Summary
GIP receptor agonism reduced PYY-induced nausea while keeping its weight-loss effect in rats; GIP antagonism boosted weight loss without worsening nausea. Both approaches may improve PYY-based obesity treatments.
Frequently Asked Questions
What is GLP-1?
The natural appetite hormone that your gut produces after eating — it's what all GLP-1 weight loss drugs (semaglutide, tirzepatide, etc.) are designed to copy. Your body makes it naturally, but it breaks down within 1-2 minutes, which is far too fast to use as a medicine. That's why drug companies created modified versions that last days instead of minutes. Included here because understanding GLP-1 is key to understanding the entire class of modern weight loss drugs.
What is GLP-1 used for?
The natural appetite hormone that your gut produces after eating — it's what all GLP-1 weight loss drugs (semaglutide, tirzepatide, etc.) are designed to copy. Your body makes it naturally, but it breaks down within 1-2 minutes, which is far too fast to use as a medicine. That's why drug companies created modified versions that last days instead of minutes. Included here because understanding GLP-1 is key to understanding the entire class of modern weight loss drugs.
What is the dosage for GLP-1?
Not used therapeutically due to extremely short half-life. Research: continuous intravenous infusion at variable rates. All approved GLP-1 therapies use modified analogues with extended half-lives instead.
What are the side effects of GLP-1?
Common: nausea and vomiting at higher doses. Serious: dangerously low blood sugar if combined with insulin or diabetes medications. Rare: allergic reactions.
How does GLP-1 work?
GLP-1 (glucagon-like peptide 1) is the native incretin hormone produced by enteroendocrine L-cells in the distal small intestine and colon in response to nutrient ingestion. It is the endogenous molecule that all GLP-1 receptor agonist drugs (semaglutide, liraglutide, etc.) are designed to mimic. Understanding native GLP-1 is essential to understanding the entire drug class built upon its biology. Upon release, GLP-1 binds to GLP-1 receptors (GLP-1R) — G protein-coupled receptors expressed on pancreatic beta cells, the GI tract, the heart, the kidneys, and critically, the brain. In the pancreas, GLP-1R activation stimulates adenylyl cyclase, raising intracellular cAMP levels, which potentiates glucose-stimulated insulin secretion. This glucose-dependence is a key safety feature — GLP-1 only promotes insulin release when blood sugar is elevated, minimizing hypoglycemia risk. Simultaneously, GLP-1 suppresses glucagon secretion from alpha cells, further reducing hepatic glucose output. In the brain, GLP-1 receptors in the hypothalamus (arcuate nucleus, paraventricular nucleus) and brainstem (area postrema, nucleus tractus solitarius) mediate appetite suppression and satiety. GLP-1 also activates vagal afferents to slow gastric emptying, prolonging nutrient absorption and post-meal satiety. The critical limitation of native GLP-1 is its extremely rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves the first two amino acids within 1-2 minutes, rendering it inactive. This ultra-short half-life is why pharmaceutical GLP-1 analogues require structural modifications (albumin binding, DPP-4 resistance) to achieve clinically useful durations of action.
How is GLP-1 administered?
GLP-1 is administered via subcutaneous injection or intravenous infusion.
What is the half-life of GLP-1?
The half-life of GLP-1 is 1-2 minutes.
Is GLP-1 legal?
Not available as an approved drug in native form. All approved GLP-1 therapies are modified analogues with extended half-lives.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
Adipotide
An extreme experimental approach to fat loss — it physically destroys the blood vessels that feed fat tissue, starving fat cells until they die. Originally developed using anti-cancer technology at MD Anderson Cancer Center. While it did reduce fat in monkey studies, it also caused serious kidney damage, which has effectively stopped its development. Not available for human use.
AICAR
A natural compound that activates your cells' energy sensor — the same pathway that turns on during exercise. Mimics the metabolic effects of endurance exercise at the cellular level, helping with fat burning, glucose uptake, and building more mitochondria. Banned by WADA as a metabolic modulator after detection in professional cycling.
AOD-9604
A small piece of human growth hormone (amino acids 176-191) designed to keep only the fat-burning effects while removing the unwanted side effects of full growth hormone (like swelling and blood sugar problems). The idea is promising — burn fat without the downsides — but it failed to show significant weight loss in clinical trials. Still widely used in research and wellness clinics despite the weak clinical evidence.